- Conditions
- Crohn's Disease
- Interventions
- VSL#3, Placebo
- Dietary Supplement
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 768
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Hematopoietic/Lymphoid Cancer, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia
- Interventions
- fludarabine phosphate, busulfan, anti-thymocyte globulin, tacrolimus, methotrexate, peripheral blood stem cell transplantation, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cancer
- Interventions
- graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
- Biological · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Up to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2004
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 6 Months to 74 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2015
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Philadelphia, Pennsylvania
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Allogeneic Hematopoietic Stem Cell Transplant Recipient, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blastic Plasmacytoid Dendritic Cell Neoplasm, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Donor, Lymphoblastic Lymphoma, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Thiotepa, Total-Body Irradiation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2025
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Seattle, Washington
- Conditions
- Bipolar Depression, Suicidal Ideation
- Interventions
- NRX-101, Lurasidone HCl
- Drug
- Lead sponsor
- NeuroRx, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Hollywood, Florida • Fort Worth, Texas + 1 more
- Conditions
- Eating Disorders, Anorexia Nervosa, Anorexia Nervosa in Remission
- Interventions
- Facing Eating Disorder Fears Condition
- Behavioral
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Phase CML, BCR-ABL1 Positive, Cytomegalovirus Positive, Donor, Hematopoietic Cell Transplant Recipient, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Myelofibrosis, Hematopoietic and Lymphoid Cell Neoplasm
- Interventions
- Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Interventions
- cyclophosphamide, cyclosporine, methotrexate, mycophenolate mofetil, sirolimus, tacrolimus, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
- Drug · Other · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Secondary Acute Myeloid Leukemia
- Interventions
- Azacitidine, Gemtuzumab Ozogamicin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 60 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2027
- U.S. locations
- 177
- States / cities
- Burbank, California • Palo Alto, California • Sacramento, California + 122 more
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Hemophagocytic Lymphohistiocytoses, Primary Immunodeficiency Diseases, Hemoglobinopathies, Severe Aplastic Anemia, Cytopenia, Bone Marrow Failure Syndrome, Severe Chronic Active Epstein-Barr Virus Infection
- Interventions
- CliniMACS
- Device
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Childhood Acute Lymphoblastic Leukemia in Remission, Obesity
- Interventions
- Phone Coaching Program
- Behavioral
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 4 Years to 10 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • Memphis, Tennessee
- Conditions
- Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer, Recurrent Ovarian Cancer
- Interventions
- WT1 Vaccine, Nivolumab, NY-ESO-1 Vaccine
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Ulcerative Colitis
- Interventions
- adalimumab, placebo
- Biological
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 576 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 25 more
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
- Interventions
- Galinpepimut-S, GM-CSF, Montanide
- Biological · Other
- Lead sponsor
- Sellas Life Sciences Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Hodgkin Lymphoma, Adult Non-Hodgkin Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, HLA-A*0201 Positive Cells Present, Myelodysplastic Syndrome, Adult Lymphoblastic Lymphoma, Chronic Lymphocytic Leukemia, Myelofibrosis, Myeloproliferative Neoplasm
- Interventions
- CMVpp65-A*0201 peptide vaccine, Placebo, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 5
- States / cities
- Duarte, California • Atlanta, Georgia • Minneapolis, Minnesota + 2 more
- Conditions
- Vasculitis, Wegener's Granulomatosis
- Interventions
- Mycophenolate Mofetil
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Graft Versus Host Disease, Leukemia
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Leukemia
- Interventions
- laboratory biomarker analysis, medical chart review, metabolic assessment, questionnaire administration, assessment of therapy complications
- Other · Procedure
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee
- Conditions
- Cancer Remission
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Interventions
- Filgrastim, Cladribine, Cyclosporine, Cytarabine (Ara-C), Fludarabine Phosphate, Idarubicin, Methylprednisolone, Peripheral Blood Stem Cell Transplantation
- Biological · Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 55 Years to 70 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2002
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 2 Diabetes, Obesity
- Interventions
- Medical weight loss, Diabetes education, Continuous glucose monitoring
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission, Non-Hodgkin Lymphoma in Remission, Cancer Survivorship
- Interventions
- Phentermine/Topiramate ER, Health Behavior and Lifestyle Counseling
- Drug · Behavioral
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 12 Years to 24 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, UV light therapy, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio